1 / 3

Performance of Veru Pharma’s Sabizabulin in Phase I/II mCRPC Trial

Veru presented meaningful results from the Phase Ib/II clinical study of Sabizabulin in men with metastatic castration-resistant prostate cancer.<br><br>https://www.delveinsight.com/asco-conference/article/veracity-trial?utm_source=Promotion&utm_medium=ASCO&utm_campaign=ConferenceCoverage

yashb
Télécharger la présentation

Performance of Veru Pharma’s Sabizabulin in Phase I/II mCRPC Trial

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Performance of Veru Pharma’s Sabizabulin in Phase I/II mCRPC Trial. Phase III VERACITY Trial Has Already Been Commenced In the Phase Ib/II clinical trial of Sabizabulin in men with metastatic castration-resistant prostate cancer, Veru published important findings. Sabizabulin Mechanism of Action: Tubulin inhibitors; Tubulin polymerization inhibitors The alpha and beta-tubulin subunits of cellular intermediate filaments and microtubules are targeted, bound, and crosslinked by the first-in-class small chemical sabizabulin, disrupting the cytoskeleton. Additionally, sabizabulin kills cells by cleaving poly ADP ribose polymerase (PARP), a crucial enzyme for cancer cells' DNA repair. The results reported at the ASCO 2022 Conference was fairly substantial in terms of the drug's efficacy, attaining a total response rate of 20.7 percent for all patients who have taken at least a 63mg dose. Additionally, 11.4 months were the median radiographic progression-free survival. Sabizabulin dosage was well tolerated in terms of safety, and there were no clinically relevant reports of neurotoxicity or neutropenia. The Phase III VERACITY trial of sabizabulin for men with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on an androgen receptor targeted drug was also started because of these data, which is significant.

  2. "The Phase 1b/2 study of the sabizabulin clinical trial demonstrated a significant 11.4 months median radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer that has progressed while receiving an androgen receptor targeting agent," according to the study. - Professional View. Conclusion Given the encouraging results of the sabizabulin ASCO 2022, we may assume that these preliminary data showed that the medicine looks to be very active in these individuals and has the potential to address a critical unmet medical need. Since the launch of docetaxel and the subsequent findings from clinical trials of novel hormonal drugs, such as abiraterone and enzalutamide, the therapeutic options for mCRPC have undergone significant evolution. A median progression-free survival of 3 to 4 months is frequently the starting point for other treatments used in these patients, such as docetaxel chemotherapy or other androgen targeting medicines. In light of these results, it may be concluded that sabizabulin appears to be fairly active in these patients and that continued oral therapy with a favourable safety profile is feasible. Moving on to the CRPC market, which is already very crowded, there is a lot of rivalry going on between the new medications, so the medication needs to have a respectable safety profile and greater efficacy to earn their valued place in the market. Sabizabulin is an exciting first-in-class medicine that could be added to the therapy arsenal for mCRPC, based on the scenario for the drug. A few rivals, including Roche, Modra Pharmaceuticals, Candel Therapeutics, Eli Lilly, Pfizer, Janssen, Clovis Oncology, Bristol-Myers Squibb, AstraZeneca, Janssen Research & Development, and others, are also assessing their lead candidates for CRPC at various levels of clinical development. To Get a Detailed analysis of ASCO Conference 2022 Abstracts, Visit: ASCO 2022 Detailed Coverage | ASCO 2022 Conference | ASCO Conference 2022 | ASCO Abstract 2022 Some of the Latest ASCO Abstract 2022 Launched: Can Breyanzi be a hit CAR-T in second-line treatment after failing in the first-line setting for the patients with R/R Large B-cell lymphoma (LBCL)? Teclistamab, a soon-to-be-approved bispecific antibody, demonstrates its promise in Multiple Myeloma during ASCO 2022. Merus’ Zenocutuzumab, a HER2-HER3 Bispecific Antibody, Successfully Targets NRG1 Fusions in Lung and Pancreatic Cancer Latest Pharmaceutical Market Research Reports 2022 by Delveinsight Hepatic Cirrhosis Market

  3. Shigellosis Market Tuberculosis Market B-Cell Maturation Antigen Targeted Therapies Market Oncolytic Virus Cancer Therapy Pipeline Coronary Microvascular Dysfunction CMD Market Medical Marijuana Market Facial Lines Market Adult T-Cell Leukemia Market Shingles Market Kaposi's Sarcoma Market Surgical Mask & Respirator Market Stem Cell Market

More Related